Salix Pharmaceuticals

What Salix Pharmaceuticals does

Salix Pharmaceuticals is a U.S. specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal (GI) diseases and disorders. Founded in 1989 in Sunnyvale, California by Randy W. Hamilton and Lorin K. Johnson, PhD, the company relocated operations to Raleigh, North Carolina in 2000 and then to Bridgewater, New Jersey in 2014, where it currently maintains its corporate headquarters at 400 Somerset Corporate Blvd. Salix was acquired by Valeant Pharmaceuticals International in January 2015; Valeant subsequently rebranded to Bausch Health Companies Inc., and Salix now operates as a wholly-owned subsidiary of that diversified pharmaceutical parent (NYSE: BHC). The company employs 501-1,000 people and self-describes as "one of the largest specialty pharmaceutical companies in the world," with over 30 years of GI-focused experience.

Salix's product portfolio centers on FDA-approved prescription medications across multiple GI conditions. Core assets include XIFAXAN (rifaximin) 200 mg and 550 mg for overt hepatic encephalopathy and IBS-D; RELISTOR (methylnaltrexone bromide) subcutaneous injection and 150 mg tablets for opioid-induced constipation; TRULANCE (plecanatide) for chronic idiopathic constipation and IBS-C; UCERIS (budesonide) rectal foam and extended-release tablets for ulcerative colitis; and PLENVU, a 1-liter PEG bowel preparation for colonoscopies. The portfolio also includes numerous acquired/long-tail brands covering UC (APRISO, COLAZAL, GIAZO), hemorrhoids (ANUSOL-HC, PROCTOCORT), bowel prep (MOVIPREP, OSMOPREP), and adjacent metabolic/cardiometabolic conditions (GLUMETZA, FENOGLIDE, DIURIL, ZEGERID, CYCLOSET). Salix does not sell a software platform, API, or technology product.

Salix monetizes through prescription pharmaceutical sales routed via retail and hospital pharmacy channels, accessed through a dedicated specialty field sales force calling on gastroenterologists, hepatologists, hospitalists, and pain management specialists, supplemented by a primary care sales force for XIFAXAN and RELISTOR. The company layers in co-promotion agreements (e.g., LUCEMYRA with US WorldMeds; DOPTELET with Dova), HCP-facing educational platforms (GastroHub), and patient assistance/copay savings programs for RELISTOR, TRULANCE, UCERIS, and XIFAXAN. Licensing activity (Mitsubishi Tanabe S1P modulator for IBD; University of California NASH compound) and M&A (Santarus 2014; Synergy assets including Trulance 2019) have been central to pipeline and portfolio expansion.

Name

Salix Pharmaceuticals

Legal name

Salix Pharmaceuticals, Inc.

Website

https://salix.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Salix Pharmaceuticals is a U.S. specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders, marketing FDA-approved prescription brands including XIFAXAN, RELISTOR, TRULANCE, UCERIS, and PLENVU. A wholly-owned subsidiary of Bausch Health Companies Inc., it sells primarily through a specialty field sales force calling on gastroenterologists, hepatologists, hospitalists, and pain specialists.

Ownership category

akta.pro rank

Product category

Gastrointestinal Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Gastrointestinal & Digestive Health (HLAIADAD)

Keywords

• Gastrointestinal pharmaceuticals
• Prescription GI drugs
• Specialty pharmaceutical company
• Bowel preparation products
• Hepatic encephalopathy treatments

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Technology or R&D, Operations, Supply Chain, Others

Revenue model

1. Prescription Pharmaceutical Products: Salix generates revenue through the sale of prescription gastrointestinal medications including XIFAXAN, RELISTOR, TRULANCE, UCERIS, PLENVU, and other GI therapeutics through pharmacy distribution channels to healthcare providers and patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Salix Pharmaceuticals develops, manufactures, and markets a portfolio of FDA-approved prescription medicines for the treatment of gastrointestinal and hepatic diseases in the United States. Its marketed brands address hepatic encephalopathy (XIFAXAN), opioid-induced constipation (RELISTOR), irritable bowel syndrome with constipation (TRULANCE), ulcerative colitis (UCERIS), and bowel preparation prior to colonoscopy (PLENVU). The company sells primarily to healthcare providers and institutional buyers through wholesale distribution and a specialty sales force.

Product overview

Salix Pharmaceuticals is a specialty pharmaceutical company and wholly-owned subsidiary of Bausch Health Companies Inc., focused on the prevention and treatment of gastrointestinal (GI) diseases and disorders. The company operates as a pharmaceutical product portfolio rather than a technology platform, offering a broad range of prescription medications. The core GI-focused products include XIFAXAN (rifaximin) for overt hepatic encephalopathy and IBS-D, RELISTOR (methylnaltrexone bromide) in both subcutaneous injection and oral tablet formulations for opioid-induced constipation, TRULANCE (plecanatide) for chronic idiopathic constipation and IBS-C, UCERIS (budesonide) in rectal foam and extended-release tablet formulations for ulcerative colitis, and PLENVU for bowel preparation before colonoscopies. The portfolio also includes numerous acquired and licensed brands treating related GI conditions such as ulcerative colitis (APRISO, COLAZAL, GIAZO), hemorrhoids (ANUSOL-HC, PROCTOCORT), as well as metabolic and cardiovascular products (GLUMETZA, FENOGLIDE, DIURIL, ZEGERID). The company does not offer a technology platform, API, or software products.

Differentiator

Problem solved

Functional benefit

Products and services

• XIFAXAN (rifaximin) FDA-approved oral prescription antibiotic (rifaximin) indicated to reduce the risk of overt hepatic encephalopathy recurrence in adults and to treat travelers' diarrhea caused by noninvasive strains of E. coli; prescribed primarily by hepatologists and gastroenterologists.
• RELISTOR (methylnaltrexone bromide) FDA-approved prescription therapy for opioid-induced constipation in adults with chronic non-cancer pain and in adults with advanced illness; available in subcutaneous and oral formulations.
• TRULANCE (plecanatide) FDA-approved oral prescription therapy indicated for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C).
• UCERIS (budesonide) FDA-approved prescription formulation of budesonide for the induction of remission in patients with active, mild to moderate ulcerative colitis.
• PLENVU FDA-approved low-volume prescription bowel preparation (polyethylene glycol-based) used to cleanse the colon in adults prior to colonoscopy.

Quantifiable outcome

• Xifaxan (rifaximin) treatment following OHE hospitalization associated with reduced risk of 30-day OHE rehospitalization
• +1 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

13 partnerships are on record, tiered core and minor.

• PulsePointcoreStrategic or Co-development Partner · 23 June 2026Salix served as an early development partner for PulsePoint's Ad Server Creative ID Reporting capability, which connects ad server creative data to individual physician-level (NPI) insights. Salix piloted the capability to enable true omnichannel personalization and segment messaging at the provider level for healthcare marketers.
• Ardelyx Inc.minorGTM or Marketing Partner · 18 March 2026Ardelyx Inc. serves as the lead partner for World IBS Day 2026, joined by Salix Pharmaceuticals as a global supporter alongside ModifyHealth, Tuutapp.net, and Monash University.
• ModifyHealthminorGTM or Marketing Partner · 18 March 2026ModifyHealth joined Salix Pharmaceuticals as a global supporter for World IBS Day 2026.
• Monash UniversityminorGTM or Marketing Partner · 18 March 2026Monash University joined Salix Pharmaceuticals as a global supporter for World IBS Day 2026.
• The U.S. Pain FoundationminorGTM or Marketing Partner · 1 January 2023Salix collaborated with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders to establish the inaugural Opioid-Induced Constipation (OIC) Awareness Day.
• International Foundation for Gastrointestinal DisordersminorGTM or Marketing Partner · 1 January 2023Salix collaborated with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders to establish the inaugural OIC Awareness Day.
• Bellamy YoungminorGTM or Marketing Partner · 1 January 2023Salix Pharmaceuticals partnered with Bellamy Young (actress and singer) for awareness and advocacy initiatives.
• Colon Cancer CoalitionminorGTM or Marketing Partner · 1 January 2022Salix and Colon Cancer Coalition joined forces for the 'Faces of Blue' story series to raise awareness of colorectal cancer screenings.
• Mitsubishi Tanabe PharmacoreOEM/ Whitelabel/ Licensing Partner · 25 April 2019Salix entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to develop and commercialize a late-stage investigational S1P modulator for the treatment of inflammatory bowel disease.
• University of CaliforniacoreOEM/ Whitelabel/ Licensing Partner · 1 April 2019Salix entered into a license agreement with the University of California to develop and commercialize a novel compound for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
• Dova PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 27 September 2018Dova Pharmaceuticals and Salix entered into an exclusive co-promotion agreement for DOPTELET (avatrombopag).
• Cedars-Sinai Medical CentercoreStrategic or Co-development Partner · 3 August 2018Salix expanded microbiome research and discovery through strategic collaboration with Cedars-Sinai Medical Center.
• US WorldMedsminorChannel Partner/ Reseller/ Distributor · 26 June 2018Salix and US WorldMeds entered into an exclusive co-promotion agreement for opioid withdrawal treatment LUCEMYRA (lofexidine).

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Large pharma with competing ulcerative colitis/IBD therapies (Xeljanz) and broader gastroenterology presence — broader portfolio but meaningful overlap with Salix's UCERIS/APRISO business.
• Merck & Co. Diversified pharma with relevant gastroenterology research programs and competitive presence in the broader specialty pharma landscape where Salix operates; a broad incumbent with overlapping HCP engagement.
• AbbVie: Through its Allergan acquisition, AbbVie holds LINZESS rights and competes with Salix's UC franchise via SKYRIZI and RINVOQ — a broad incumbent with overlapping GI and IBD biologics that compete for the same gastroenterology budget.
• Sanofi: Global pharma with gastroenterology and inflammatory bowel disease programs (Dupixent in EoE/IBD-adjacent) overlapping the HCP gastroenterology channel Salix serves — a broader incumbent with intersecting GI strategy.
• Eli Lilly: Large pharma with emerging gastroenterology assets and competing immunology programs relevant to Salix's UC and IBD-adjacent portfolio; comparable as a broad incumbent competitor in the HCP specialty channel.
• Takeda Pharmaceutical: Global pharma with a major GI franchise (Entyvio for IBD, Shire legacy products) competing against Salix in ulcerative colitis and broader gastroenterology; broader portfolio but materially overlapping indications.

Direct peers

• Ardelyx: Specialty GI company that developed tenapanor (IBSRELA/XPHOZAH), addressing IBS-C and hyperphosphatemia; directly comparable as a smaller GI-pure-play rival also targeting the same prescriber base.
• Ferring Pharmaceuticals: Privately-held specialty pharma with a deep GI franchise (e.g., REBYOTA for C. difficile, gastroenterology focus); comparable as a peer specialty company pursuing similar gastroenterology HCP channels.
• Sebela Pharmaceuticals: US-focused specialty pharma with GI products (e.g., Teglutik, Pizensy/lactulose franchise); closely comparable as a US-centric, GI-focused specialty company with a similar enterprise sales model.
• Ironwood Pharmaceuticals: GI-focused specialty pharma that co-markets LINZESS (linaclotide) for IBS-C and chronic idiopathic constipation — Salix's TRULANCE competes head-to-head in this category, making the two direct US competitors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/salixpharma
• LinkedInlinkedin.com/company/salix-pharmaceuticals
• Facebookfacebook.com/salixpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Salix Pharmaceuticals